Journals / Cukurova Medical Journal / 2013 / Cilt: 38 - Sayı: 3

Canavan Disease: Three case report

Canavan Hastalığı: 3 Olgu Sunumu

Pages
495–498
Publication Date
2013-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We reported three patients with psychomotor developmental delay, hypotonia and macrocephaly, who was diagnosed as Canavan disease after the investigations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Canavan disease, is an autosomal recessive disorder caused by decreased function of the enzyme aspartoacylase.
📊
Key Findings & Data:The clinical symptoms include macrocephaly, hypotonia, developmental delay, seizures, optic atrophy and dystonia.
💡
Conclusion & Impact:We reported three patients with psychomotor developmental delay, hypotonia and macrocephaly, who was diagnosed as Canavan disease after the investigations.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Canavan hastalığı · makrosefali · gelişme geriliği

Abstract

Canavan disease, is an autosomal recessive disorder caused by decreased function of the enzyme aspartoacylase. The clinical symptoms include macrocephaly, hypotonia, developmental delay, seizures, optic atrophy and dystonia. We reported three patients with psychomotor developmental delay, hypotonia and macrocephaly, who was diagnosed as Canavan disease after the investigations.

Özet

Canavan hastalığı, aspartoaçilaz enziminin yetersiz fonksiyon göstermesine bağlı olarak gelişen otozomal resesif bir hastalıktır. Makrosefali, hipotoni, gelişme geriliği, nöbetler, optik atrofi ve distoni gibi klinik bulgular eşlik edebilmektedir. Psikomotor gelişme geriliği, hipotoni ve makrosefalisi olan, yapılan tetkikleri sonucunda Canavan hastalığı tanısı alan 3 hastayı sunduk.

🔖

Cite This Article

İNCECİK, F., SIZMAZ, E. G., HERGÜNER, M. Ö., ALTUNBAŞAK, Ş. (2013). Canavan Disease: Three case report. Cukurova Medical Journal, Cilt: 38 - Sayı: 3, 495–498. https://ajindex.com/articles/57127

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Rady LP, Vargas T, Tyring SK, Matolon R. Novel missence mutation (Y231C) in a patient Canavan Disease. Am J Genet. 1999; 87: 273-5.
  2. Gerald M, Fenichel MD. Aspartoacyilase Deficiency (Canavan Disease). Clinical Pediatric Neurology USA Third Edition. 1997; 141-2.
  3. Matalon R, Michals K, Kaul R. Canavan Disease: Spongy degeneration to molecular analysis. J Pediatr. 1995; 127: 511-7.
  4. Perlman SJ, Mar S. Leukodystrophies. Adv Exp Med Biol. 2012; 724:154-71. Gordon N. Canavan disease: a review of recent developments. Europ J Pediatr Neurol. 2001; 5: 65-9. Patay Z. Diffusion-weighted MR imaging in leukodystrophies. Eur Radiol. 2005; 15: 2284-2303. Matalon R. Canavan disease diagfnosis and molecular analysis. Genet Test. 1997; 1: 21-5.
  5. Kaul R, Gao PG, Matalon R, Aloya M, Su Q, et al. Identification and expression of eight novel mutations among non-jewish patients with Canavan Disease. Am J Hum Genet. 1996; 59: 95-102.
  6. Topçu M, Yalnızoğlu D, Saatci I, et al. Effect of topiramate on enlargement of head in Canavan disease: a new option for treatment of megalencephaly. Turk J Pediatr. 2004; 46: 67-71. Yazışma Adresi / Address for Correspondence: Dr. Faruk İncecik Çukurova Üniversitesi Tıp Fakültesi, Çocuk Nöroloji Bilim Dalı 01330 Balcalı-ADANA e-mail: [email protected] geliş tarihi/received:06.11.2012 kabul tarihi/accepted:26.12.2012